Startup profile · funding coverage
T-Therapeutics funding, valuation and investors
Cambridge biotechnology company developing T-cell receptor bispecific medicines for cancer and autoimmune disease.
Verified company research · funding, investors and latest developments
Keep track of T-Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$133M · November 5, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$224M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Cambridge, United Kingdom
Investors in latest funding
Lead: Advent Life Sciences , British Business Bank
Other: Samsara BioCapital , M-Ventures , Eli Lilly
Overview
T-Therapeutics is a Cambridge biotechnology company developing soluble TCR-based medicines that target disease-associated peptide–MHC complexes, including antigens derived from intracellular proteins. Its OpTiMus platform finds TCR binders and its T-Bridge approach engineers TCR-CD3-Fc molecules to recruit T cells. Oncology candidate TTX-008 is preclinical/IND-enabling; TTX-018 immunology is discovery-stage.
No approved medicine, commercial pricing, revenue, or disclosed valuation is established.
Why T-Therapeutics is interesting
Announced a $133M Series B co-led by Advent Life Sciences and British Business Bank on November 5, 2026; developing OpTiMus TCR discovery and T-Bridge TCR-CD3-Fc bispecific programs.
Product & use cases
Research-stage drug-discovery platform, not a purchasable medicine: discover a disease-specific peptide–MHC target; identify and screen human TCRs; engineer a soluble TCR-CD3-Fc bispecific candidate; validate selectivity, toxicology and manufacturing; seek authorization for human trials; evaluate safety, response and benefit. TTX-008 and TTX-018 have not established clinical efficacy.
- Investigational T-cell recruitment against cancer cells bearing matching peptide–MHC targets.
- Discovery-stage immunology program investigating TCR-targeted disease intervention.
Funding history (newest first)
Series B
2026-11-05 $133M- Advent Life Sciences (lead)
- British Business Bank (lead)
- Samsara BioCapital (participant)
- M-Ventures (participant)
- Eli Lilly (participant)
Series A extension, incremental
2025-11-13 $32M; total Series A $91MSource: Read source · t-therapeutics.com
Series A initial
2023-11-15 $59MSource: Read source · t-therapeutics.com
Competitive landscape
Edge: Potential access to intracellular disease antigen presentation via peptide–MHC; risks include HLA restriction, off-target binding and severe immune reactions.
-
Immunocore direct
Soluble TCR-based bispecific immunotherapies with a different clinical and commercial maturity.
-
Immatics direct
TCR-based oncology medicines and bispecific molecules; distinct targets and clinical status.
-
Adaptimmune adjacent
Engineered TCR cell-therapy approach instead of soluble bispecific format.
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.